Co-Diagnostics (NASDAQ:CODX) announces that partner privately held Clinical Reference Laboratory (CRL) has received the FDA nod for the emergency use of CRL Rapid Response, a saliva-based COVID-19 test for which samples can be self-collected using CODX’s patented CoPrimer technology.
https://seekingalpha.com/news/3598875-co-diagnostics-up-7-on-u-s-launch-of-covidminus-19-saliva-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.